Frequently asked questions
The global canine CRP immunoassay market was valued at USD XX Billion in 2022.
The canine CRP immunoassay market is anticipated to grow at a CAGR of 8.5% between 2023 and 2030, reaching USD XX Billion in 2030.
Kits & Reagents are the leading segment by product type, holding over 62% share in terms of value in 2022.
The ELISA (Enzyme-Linked Immunosorbent Assay) segment governs the demand for canine CRP immunoassays worldwide, holding a massive share of over 40% in 2022.
The research segment will post the highest CAGR in the projected period.
Asia Pacific is fuelling the rapid growth of the canine CRP immunoassay industry, with an over one-third share in 2022.
The top players include ACON Laboratories Inc, Bio-Rad Laboratories Inc, and Heska Corporation. Other major players include Bionote Inc, IDEXX Laboratories Inc, Zoetis Inc, and Randox Laboratories Ltd.
The major market drivers of the canine CRP immunoassay industry include growing awareness of inflammatory disorders in dogs, increasing pet ownership, and the demand for reliable diagnostic tools.
The major market restraints of the canine CRP immunoassay industry include the limited availability of skilled professionals, high costs associated with diagnostic tests, and stringent regulatory requirements.
The major market opportunities of the canine CRP immunoassay industry include advancements in immunoassay technologies, expanding veterinary healthcare infrastructure, and the rising demand for personalized veterinary diagnostics.